Mouse models of non-hodgkin lymphoma reveal Syk as an important therapeutic target

Blood

Volumn 113, Issue 11, 2009, Pages 2508-2516

  Young, Ryan M ^a,b   Hardy, Ian R ^b   Clarke, Raedun L ^b   Lundy, Nicolai ^a   Pine, Polly ^c   Turner, Brian C ^a   Potter, Terry A ^b   Refaeli, Yosef ^a,b,d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c RIGEL PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 406; R 788; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR REGRESSION;

EID: 63849309885     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-158618     Document Type: Article

References (38)

1. Dameshek W, Schwartz RS. Leukemia and auto- immunization: some possible relationships. Blood. 1959;14:1151-1158.
2. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
3. Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol. 2007;14: 375-381.
4. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. On- cogene. 2001;20:5580-5594.
5. Adams JM, Harris AW, Pinkert CA, et al. Thec- myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in trans- genic mice. Nature. 1985;318:533-538.
6. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. The B-cell antigen receptor and overexpression of MYC can cooperate in the genesis of B-cell lymphomas. PLoS Biol. 2008;6:e152.
7. Galler GR, Mundt C, Parker M, Pelanda R, Martensson IL, Winkler TH. Surface mu heavy chain signals down-regulation of the V(D)J-recombinase machinery in the absence of surrogate light chain components. J Exp Med. 2004; 199:1523-1532.
8. Rui L, Goodnow CC. Lymphoma and the control of B-cell growth and differentiation. Curr Mol Med. 2006;6:291-308.
9. Refaeli Y, Field KA, Turner BC, Trumpp A, Bishop JM. The protooncogene MYC can break B-cell tolerance. Proc Natl Acad Sci USA. 2005;102: 4097-4102.
10. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by in- ducible gene targeting results in rapid cell death. Cell. 1997;90:1073-1083.
11. Kraus M, Pao LI, Reichlin A, et al. Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphor- ylation modulates or blocks B-cell development, depending on the availability of an Igbeta cyto- plasmic tail. J Exp Med. 2001;194:455-469.
12. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B-cell antigen receptor signaling 101. Mol Immunol. 2004;41:599-613.
13. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995; 378:298-302.
14. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303-306.
15. Orchard J, Ibbotson R, BestG, ParkerA, Oscier D. ZAP-70 in B-cell malignancies. Leuk Lym-phoma. 2005;46:1689-1698.
16. Chen L, Monti S, Juszczynski P, et al. SYK-de- pendent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lym- phoma. Blood. 2008;111:2230-2237.
17. Young RM, Zheng X, Holowka D, Baird B. Recon- stitution of regulated phosphorylation of Fcepsil- onRI by a lipid raft-excluded protein-tyrosine phosphatase. J Biol Chem. 2005;280:1230-1235.
18. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998-1008.
19. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D. Uncoupling IL-2 signals that regulate T-cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity. 1999;11:281-288.
20. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med. 2002; 196:999-1005.
21. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2- regulated Fas-mediated T-cell apoptosis. Immunity. 1998;8:615-623.
22. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, KhvorovaA. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22: 326-330.
23. Ventura A, MeissnerA, Dillon CP, et al. Cre-lox- regulated conditional RNAinterference from transgenes. Proc Natl Acad Sci U S A. 2004;101: 10380-10385.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. Arapid and simple method for measuring thymocyte apoptosis bypropidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
25. Earnshaw WC. Nuclear changes in apoptosis. Curr Opin Cell Biol. 1995;7:337-343.
26. Smith SH, Reth M. Perspectives on the nature of BCR-mediated survival signals. Mol Cell. 2004; 14:696-697.
27. Monroe JG. Ligand-independent tonic signaling in B-cell receptor function. Curr Opin Immunol. 2004;16:288-295.
28. Leseux L, Hamdi SM, Al Saati T, et al. Syk-depen- dent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156-4162.
29. Wossning T, Herzog S, Kohler F, et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006;203:2829-2840.
30. Hsueh RC, HammillAM, Lee JA, Uhr JW, Scheuermann RH. Activation of the Syk tyrosine kinase is insufficient for downstream signal trans- duction in B lymphocytes. BMC Immunol. 2002;3: 16.
31. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303-316.
32. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol. 2001;13:299-306.
33. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007;109:2032- 2039.
34. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev. 2007;7:102-108.
35. Casella G, Buda CA, Maisano R, Schiavo M, Perego D, Baldini V. Complete regression of primary gastric MALT-lymphoma after double eradication Helicobacter pylori therapy: role and importance of endoscopic ultrasonography. Anticancer Res. 2001;21:1499-1502.
36. Montalban C, Santon A, Boixeda D, Bellas C. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut. 2001;49:584-587.
37. Zhang L, French RR, Chan HT, et al. The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther Immunol. 1995;2:191-202.
38. Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616 623.